#Italy #Milan #NTC014 #bacterial conjunctivitis #Eye Care

NTC Reports Positive Outcomes from Phase II Mirakle Study

NTC, a globally recognized pharmaceutical firm based in Italy, has announced encouraging findings from its Phase II MIRAKLE study focused on a new treatment for bacterial conjunctivitis. The multicenter, double-blind, randomized study assessed the safety and effectiveness of NTC014, a unique combination of a quinolone antibiotic and NSAID, administered as eye drops.

Study Highlights

Despite utilizing a lower dosage—25% less antibiotic compared to traditional treatment—the results indicated that NTC014 demonstrates non-inferiority to the standard antibiotic treatment regarding microbiological eradication. Notably, the study showed unanticipated effectiveness against strains classified as Intermediate or Resistant to the antibiotic being tested.

Alessandro Colombo, NTC's Chief Scientific Officer, shared, "These initial results offer robust support that NTC014 can serve as a viable option for bacterial conjunctivitis treatment. This innovation contributes to our mission of reducing antibiotic usage while still addressing antibiotic resistance, allowing shorter treatment durations without restrictions even in instances of uncertain bacterial etiology."

Industry Context

According to CEO Riccardo Carbucicchio, the emergence of NTC014 marks the first instance globally of an antibiotic combined with an NSAID for this condition. The ongoing need for effective treatments for moderate to severe bacterial conjunctivitis, a prevalent eye infection, highlights the significance of these findings. With a dire lack of sufficient medical treatments available, the potential of NTC014 could be monumental in meeting this need.

The company is actively pursuing commercial partnerships to launch this promising therapy across global markets by the end of 2025, with considerations for surgery-related applications as well.

Conjunctivitis Landscape

Conjunctivitis, especially in Western nations, imposes both economic and social challenges. While viral conjunctivitis remains the predominant cause, accounting for most cases in adults, bacterial conjunctivitis leads to approximately 50% to 75% of infections in children.

NTC has already made its mark by successfully introducing the first-ever combination of a quinolone antibiotic and a steroid for post-cataract surgery, a product currently marketed in over 60 countries. This successful precedent underlines the company's capabilities and sets the stage for NTC014's potential impact.

About NTC

Founded in Milan, Italy, NTC is dedicated to researching, developing, and commercializing innovative drugs and medical devices. The company currently partners with distributors across more than 100 countries to serve a diverse array of medical specialties, including ophthalmology, pediatrics, gynecology, and gastroenterology. Offering over 200 partners high-standard pharmaceutical products, NTC is poised to make significant contributions to global health solutions.

More details about NTC's efforts and their innovative products are available on their website: www.ntcpharma.com.